纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | SNCA |
Uniprot No | P37840 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-140aa |
氨基酸序列 | MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVH GVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQL GKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA |
预测分子量 | 14 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SNCA(α-突触核蛋白)重组蛋白的3篇代表性文献名称、作者及摘要内容概括:
1. **"Recombinant α-synuclein fibrils induce Lewy body pathology in primary neurons"**
- **作者**: Volpicelli-Daley, L.A. et al. (2014)
- **摘要**:研究利用重组SNCA蛋白体外形成纤维,证实其可诱导神经元内类似帕金森病的路易小体病理特征,揭示了α-突触核蛋白聚集的致病机制。
2. **"Structural characterization of recombinant human α-synuclein fibrils by cryo-electron microscopy"**
- **作者**: Guerrero-Ferreira, R. et al. (2018)
- **摘要**:通过冷冻电镜解析重组人源SNCA蛋白纤维的高分辨率结构,揭示其β折叠层状排列模式,为理解病理性聚集提供分子基础。
3. **"Purification and characterization of recombinant α-synuclein polymers"**
- **作者**: Wood, S.J. et al. (1999)
- **摘要**:早期研究描述了大肠杆菌表达系统制备重组SNCA蛋白的方法,并分析其体外自组装为淀粉样纤维的条件及动力学特性。
如需具体文献,建议通过PubMed或Web of Science检索标题或作者获取全文。
**Background of SNCA Recombinant Protein**
The *SNCA* gene encodes alpha-synuclein (α-synuclein), a small, intrinsically disordered protein predominantly expressed in neuronal tissues. It is implicated in synaptic vesicle dynamics, neurotransmitter release, and lipid membrane interactions. Pathologically, α-synuclein is the primary component of Lewy bodies and Lewy neurites, proteinaceous aggregates characteristic of Parkinson’s disease (PD), dementia with Lewy bodies, and other synucleinopathies. Mutations or multiplications in *SNCA* are genetically linked to familial and sporadic forms of these neurodegenerative disorders, underscoring its central role in disease pathogenesis.
Recombinant SNCA protein refers to α-synuclein produced *in vitro* using genetic engineering techniques, typically expressed in bacterial (e.g., *E. coli*) or mammalian cell systems. This approach allows for high-yield, purified protein with controlled post-translational modifications (PTMs), enabling precise study of its structure, aggregation mechanisms, and interactions. Recombinant α-synuclein is widely used to model pathological processes *in vitro*, such as fibril formation, seeding activity, and toxicity in cellular assays. It also serves as a critical tool for screening therapeutic compounds targeting α-synuclein aggregation.
Despite its utility, challenges persist in replicating disease-relevant PTMs (e.g., phosphorylation, ubiquitination) and conformational states (monomers, oligomers, fibrils) seen in human brains. Advances in expression systems (e.g., cell-free, yeast) and biophysical techniques (NMR, cryo-EM) have improved the production of recombinant α-synuclein variants that better mimic native or pathological forms. Current research focuses on elucidating structure-function relationships, identifying aggregation inhibitors, and developing biomarkers or immunotherapies for synucleinopathies.
In summary, recombinant SNCA protein is indispensable for unraveling the molecular basis of α-synuclein-related neurodegeneration and accelerating translational research in PD and related disorders.
×